- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001046
Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
PRIMARY: To evaluate the short-term safety of rgp120/HIV-1SF2 vaccine versus MF59 placebo administered to HIV-infected pregnant women.
SECONDARY: To evaluate the immunogenicity and long-term safety of rgp120/HIV-1SF2 in HIV-infected pregnant women who received the vaccine during pregnancy only or during pregnancy and postpartum. To evaluate immunogenicity and safety in the infant through 18 months of age following maternal immunization with the vaccine during pregnancy.
Active immunization of HIV-infected women during pregnancy may slow the progression of maternal disease, reduce the titer of virus in maternal plasma, and increase the titer of epitope-specific antibody. Also, active immunization has the potential to induce primary immunity in the fetus and to boost both T-cell and humoral immune responses to HIV in the mothers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Active immunization of HIV-infected women during pregnancy may slow the progression of maternal disease, reduce the titer of virus in maternal plasma, and increase the titer of epitope-specific antibody. Also, active immunization has the potential to induce primary immunity in the fetus and to boost both T-cell and humoral immune responses to HIV in the mothers.
Women are randomized to receive rgp120/HIV-1SF2 vaccine or MF59 placebo. Patients receive the first immunization between 16 and 24 weeks gestation and monthly thereafter until delivery, for a maximum of five immunizations. Patients may continue to receive the immunization regimen to which they were originally assigned at 3, 6, 9, and 12 months postpartum. Maternal follow-up continues until 18 months postpartum; infants are followed until age 18 months.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed during pregnancy:
- AZT.
- Methadone maintenance.
NOTE:
- Patients may not initiate antiretroviral therapy for disease progression.
NOTE:
- Patients may change from AZT to another antiretroviral agent or may begin antiretroviral therapy following delivery, if clinically indicated.
Patients must have:
- Documented HIV infection.
- CD4 count >= 400 cells/mm3 (average of two determinations obtained 1 week apart).
- No clinical criteria for a diagnosis of AIDS.
- HIV p24 antigen <= 30 pg/ml.
- Estimated gestational age between 16 and 24 weeks, confirmed by baseline sonogram that does not demonstrate any congenital abnormalities considered to be incompatible with life.
- Intention to carry pregnancy to term.
- Willingness to be followed by an ACTU for the duration of the study.
NOTE:
- Father of the fetus (if available after a reasonable attempt to contact him) must provide informed consent.
Prior Medication:
Allowed:
- AZT.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Known hypersensitivity to a component of the vaccine.
- Hepatitis B antigen positive at study entry.
- Evidence of life-threatening or other serious pre-existing fetal abnormalities (e.g., anencephaly, renal agenesis, Potter's syndrome).
- Evidence of syphilis that requires therapy during this pregnancy.
- Intention to breast-feed.
Presence of obstetrical high-risk factors such as:
- insulin-dependent diabetes
- hypertension requiring the use of anti-hypertensive therapy
- repeated intrauterine fetal demise
- Rh-sensitization or other blood group alloimmunization
- diseases requiring use of immunosuppressive therapy (e.g., asthma, lupus).
Concurrent Medication:
Excluded during pregnancy:
- Antiretrovirals other than AZT.
- Immunomodulating agents (e.g., HIVIG, IVIG).
- Other investigational drugs or immunosuppressive agents.
NOTE:
- Patients may change from AZT to another antiretroviral agent or may begin antiretroviral therapy following delivery, if clinically indicated.
Prior Medication:
Excluded within 90 days prior to study entry:
- Antiretrovirals other than AZT.
- Immunomodulating agents (e.g., HIVIG, IVIG).
Current use of illicit drugs or chronic alcohol use by patient history.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Interventional Model: Parallel Assignment
Collaborators and Investigators
Investigators
- Study Chair: Starr S
- Study Chair: Allen M
- Study Chair: Silverman N
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACTG 233
- 11210 (Registry Identifier: DAIDS ES Registry Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on rgp120/HIV-1 SF-2
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; MicroGeneSys Inc (nka Protein Sciences Corporation)Completed
-
National Institute of Allergy and Infectious Diseases...BiocineCompleted
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; BiocineCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; BiocineCompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...BiocineCompletedHIV InfectionsUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed